Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
RESEARCH ARTICLE Terminal Respiratory Unit Type Lung Adenocarcinoma is Associated With Distinctive EGFR Immunoreactivity and EGFR Mutations Michael R. Peterson, MD, PhD,* Zhe Piao, MD, PhD,* Lyudmila A. Bazhenova, MD,w Noel Weidner, MD,* and Eunhee S. Yi, MD* important roles in the proliferation and metastasis of Abstract: Approximately 10% to 20% of nonsmall cell lung tumor cells. EGFR is a favored target for orally cancer patients respond to epidermal growth factor receptor administered small-molecule and antibody-based therapy. (EGFR) tyrosine kinase inhibitors, such as gefitinib. Responders Nonsmall cell lung cancer frequently expresses EGFR are mostly nonsmokers and women with tumors displaying and two EGFR inhibitors [gefitinib (Iressa, Astra- bronchioloalveolar features. Mutations of the tyrosine kinase Zeneca) and erlotinib (Tarceva, OSI Pharmaceuticals)] domain of the EGFR gene have been associated with a clinical have been approved by the FDA as third-line therapy for response to gefitinib. A recent study reported that the terminal nonsmall cell lung cancer since May 2003. respiratory unit (TRU)-type adenocarcinoma shares the clinical Clinical trials using gefitinib have shown a response profile and EGFR mutations of gefitinib responders. EGFR rate of approximately 10% to 20%. Phase 2 studies have immunoreactivity in this context has not been reported
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Sep 1, 2007
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.